Immuno-Oncology Webinar: Different Routes To The Same Destination
This article was originally published in Scrip
Bristol-Myers Squibb has shot out of the starting gate in the great immuno-oncology race, with Merck & Co hot on its tail. Frenzied deal making and exponential growth in the number of investigational products and clinical trials taking place suggest, however, that there is ample room for a range of players in this market.
Register for our free email digests: